According to InvestingPro’s fair value feature, Biocon’s intrinsic valuation stands at INR 388.1 per share, indicating a potential upside of 11.7% from the current market price (CMP) of INR 347.5.

Biocon aims to grow through new product launches in generics and biosimilars, bolstered by the Viatris acquisition. This strategy integrates development, production, distribution, and market ...

Objective: We sought to evaluate the efficacy and safety of vildagliptin, a new dipeptidyl peptidase-4 inhibitor, added to metformin during 24 weeks of treatment in patients with type 2 diabetes.